
To report efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS). In the SELECT‐AXIS 1 study, adults with active AS and inadequate response to non‐steroidal anti‐inflammatory drugs were randomized to upadacitinib 15 mg once daily (QD) or placebo. At week 14, patients continued in the open‐label extension and received upadacitinib up to week 104; reported here are interim data up to week 64...
Like
Save
Share